Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharmaceuticals Sector Analysis Report 

[Key Points | Financial Year '19 | Prospects | Sector Do's and dont's]

Opportunity Ends Soon: Discover Tanushree's Top 7 Stocks for 2020 virtually FREE.

  • India enjoys a key position in the global pharmaceutical industry. The country is the world’s largest supplier of generics, accounting for 20% of global exports. It supplies over 50% of global demand for various vaccines and 40% of the demand for generic products in the US. The domestic pharmaceutical market contributes to ~2% of the global industry in value and ~10% in volume terms.
  • The domestic pharmaceutical industry has received foreign direct investment (FDI) worth US$ 16 billion on a cumulative basis, between April 2000 and June 2018.
  • The industry has played a key role in driving better health outcomes across the world through its affordable and high-quality generics drugs. Increased accessibility to affordable drugs has been one of the key enablers for lowering the disease burden in India. India’s per person disease burden measured as Disability Adjusted Life Years (DALYs) dropped by 36% justing for changes in the population age structure.
  • During the year, drug penetration in India increased by 50%. India has now become Polio-free5, as a result of strong collaboration among vaccine manufacturers, healthcare providers, the government and development organisations.
  • The industry has also helped in bringing down the treatment costs of life-threatening diseases such as Chronic Myeloid Leukemia and Hepatitis C, to less than 5% of the original cost.
  • India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.

How to Research the Pharmaceutical Sector (Key Points)

  • Supply
  • Higher for traditional therapeutic segments, this is typical of a developing market. Relatively lower for lifestyle segment.
  • Demand
  • Very high for certain therapeutic segments. Will change as life expectancy, literacy increases.
  • Barriers to entry
  • Distribution network, patents, developing and manufacturing capabilities,
  • Bargaining power of suppliers
  • Varies from market to market For instance, consolidation in US has led to pricing war in generics, In India, distributors are increasingly pushing branded products in a bid to earn higher margins.
  • Bargaining power of buyers
  • High, a fragmented industry has ensured that there is widespread competition in almost all product segments. Currently, the domestic market is also protected by the DPCO.
  • Competition
  • High and fragmented owing to many small players in the industry.

top ↑

Financial Year '19

  • The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4% over 2015–20 to reach US$ 55 billion. The pharmaceutical sector was valued at US$ 33 billion in the previous year.
  • India’s pharmaceutical exports stood at US$ 17.27 billion in FY18 and reached US$ 19.14 billion in FY19. Pharmaceutical exports include bulk drugs, intermediates, drug formulations, biologicals, Ayush & herbal products and surgicals.
  • The exports of Indian pharmaceutical industry to the US will get a boost, as branded drugs worth US$ 55 billion will become off-patent during 2018-2019. For the US market, Indian companies are developing niche portfolios in various segments. High margin injectables, dermatology, respiratory, biosimilars, complex generics etc. have become an area of interest. Most of the Indian pharma companies have been working on these. Major companies have increased their R&D spend to build pipeline of niche drugs.
  • The National Health Protection Scheme is largest government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh (US$ 7,723.2) per family per year for secondary and tertiary care hospitalization. The programme was announced in Union Budget 2018-19.
  • The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.
  • Exchange Rate Used: INR 1 = US$ 0.0159 as on March 31, 2019.

top ↑

Prospects

  • Pharmaceutical spending in developed markets is likely to grow at 2-5% CAGR between 2018-22 compared to 5.8% in the 2013-17 period. While launch of innovative products is likely to drive growth, is expected to be balanced by patent expiries of existing products.
  • Innovation in new drug development, immunotherapy, next generation biotherapeutics, including cell-based gene therapies and digital health tools will gain importance in the future of the healthcare industry.
  • India and Russia are expected to grow faster, in comparison, averaging at 10% in the same time span, while the other pharma emerging markets will average 6-9%.
  • Global population is projected to exceed 9.3 billion by 2050, of which 21% will be accounted for by those aged 60 and above. As individuals become increasingly health conscious and medical science continues to advance, life expectancy will increase. By 2040, Japan, Singapore, Spain and Switzerland are projected to have a life expectancy rate in excess of 85 years, while 59 countries, including China, are expected to surpass a life expectancy of 80 years during that period.
  • Growth in global pharmaceutical spending through 2023 will primarily be driven by developed markets and the accelerated adoption of new innovative products. Spending on medicines in developed markets is estimated to grow at 3-6% CAGR from US$ 800 Billion in 2018 to US$ 990-1,020 Billion in 2023.
  • All developed countries will show moderation in growth through 2023, as compared to the 2014-18 period. Specifically in the US, the positive impact of new specialty launches will be partly moderated by loss of patent protection on older products.

top ↑

Related Links for Pharmaceuticals Sector
Quarterly Results | Sector Quote | Over The Years

Views on News

J.B.CHEMICALS Surges by 5%; BSE HEALTHCARE Index Down 0.3% (Market Updates)

Feb 26, 2020 | Updated on Feb 26, 2020

J.B.CHEMICALS share price has surged by 5% and its current market price is Rs 563. The BSE HEALTHCARE is down by 0.3%. The top gainers in the BSE HEALTHCARE Index is J.B.CHEMICALS (up 5.0%). The top losers are APOLLO HOSPITALS (down 0.3%) and LAURUS LABS LTD (down 0.4%).

SANOFI INDIA at All Time High; BSE HEALTHCARE Index Down 0.5% (Market Updates)

Feb 26, 2020 | Updated on Feb 26, 2020

SANOFI INDIA share price has hit an all time high at Rs 7,638 (up 3.2%). The BSE HEALTHCARE Index is down by 0.5%. Among the top gainers in the BSE HEALTHCARE Index today are SANOFI INDIA (up 3.2%) and PFIZER (up 2.1%). The top losers include GSK PHARMA (down 0.2%) and DR. REDDYS LAB (down 0.3%).

SANOFI INDIA at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Feb 26, 2020 | Updated on Feb 26, 2020

SANOFI INDIA share price has hit an all time high at Rs 7,638 (up 3.1%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are SANOFI INDIA (up 3.1%) and ABBOTT INDIA (up 1.6%). The top losers include BLISS GVS PHARMA (down 0.1%) and SYNGENE INTERNATIONAL (down 0.1%).

SANOFI INDIA Surges by 7%; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Feb 26, 2020 | Updated on Feb 26, 2020

SANOFI INDIA share price has surged by 7% and its current market price is Rs 7,515. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index is SANOFI INDIA (up 7.3%). The top losers are IPCA LABS and PFIZER (down 0.1%).

CIPLA Plunges by 5%; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Feb 26, 2020 | Updated on Feb 26, 2020

CIPLA share price has plunged by 5% and its current market price is Rs 402. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index are SANOFI INDIA (up 7.3%) and SUVEN LIFESCIENCES (up 5.0%). The top losers is CIPLA (down 5.4%)..

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks (Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat Views On News (Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid (Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock (Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

These Rebirth of India Stocks Are Raring to Compete with Tesla (The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Feb 26, 2020 (Close)

COMPARE COMPANY

MARKET STATS